Cardiosonic

Ultrasonic Energy Solution for Resistant Hypertension

Health Tech & Life Sciences
Non Active, Jul 2019 ceased to operate
Mature Tel Aviv-Yafo, Israel Founded 2009
LinkedIn
Last updated 2026-06-18
Total raised
$8.6M
Last: 2015-11
Stage
Mature
Founded
2009
Headcount
31
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Cardiosonic develops solutions for transluminal, high-intensity ultrasound ablation. The company's flagship application, the TIVUS high-intensity, directional ultrasound catheter system, enables remote, localized, controlled, and repeatable thermal modulation of the renal vessel wall tissue, to perform safe, therapeutic renal sympathetic denervation by ultrasound ablation for resistant hypertension. The TIVUS system consists of the TIVUS catheter and the TIVUS control console. Ultrasound waves are transmitted from the tip of the TIVUS catheter through the arterial wall to ablate the surrounding renal nerves. Renal nerve ablation resets the body's sympathetic tone/drive and results in blood pressurereduction. The TIVUS console enables the interventionalist to control the parameters (e.g. treatment intensity and duration) of the treatment, which lasts less than 10 minutes.

Funding history · 2 rounds · $8.6M total

2015-11
$2.5M
2012-12

Q&A

What is Cardiosonic's primary focus?
Cardiosonic develops solutions for transluminal, high-intensity ultrasound ablation, specifically targeting resistant hypertension with its TIVUS catheter system.
When was Cardiosonic founded?
Cardiosonic was founded in October 2009.
What is the current status of Cardiosonic?
Cardiosonic is currently inactive, having ceased operations in July 2019.
What is Cardiosonic's flagship product?
Cardiosonic's flagship product is the TIVUS high-intensity, directional ultrasound catheter system, designed for therapeutic renal sympathetic denervation.
How much total funding has Cardiosonic raised?
Cardiosonic has raised a total of $8,600,000.
When was Cardiosonic's last funding round?
Cardiosonic's last funding round occurred in November 2015, raising $2,500,000.
Who was an investor in Cardiosonic's December 2012 funding round?
Shmuel Almagor was an investor in Cardiosonic's December 2012 funding round.
How many employees did Cardiosonic have?
Cardiosonic had 11-50 employees.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Simulation & ImagingUltrasound
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Tags

ultrasoundblood-pressurecathetersmedical-devicestreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)